Baxter International Inc. (NYSE:BAX) dropped
0.57% to $50.78. The company said
Thursday that third-quarter earnings were $595 million, of $1.01 a share
compared to $530 million, or 88 cents a share, in the year-ago period.
Analysts
polled by FactSet research estimated, on average, earnings per share of 98
cents and sales of $3.16 billion. The company sees fourth-quarter sales growth
of 1% to 2% and earnings per share of $1.09 to $1.11.
The
stock went down more than 13% year-to-date.
Boston Scientific Corporation (NYSE:BSX)
added
0.63% to $6.38. The company announced that its WallFlex Biliary RX Fully
Covered Stent has received CE Mark approval for the treatment of benign biliary
strictures.
The
stock opened at $6.36 and is trading within the range of $6.17-$6.70.
Eli Lilly & Co. (NYSE:LLY) dropped
0.31% to $35.39. The company said it earned $1.3 billion, or $1.18 a share,
compared with $942 million, or 86 cents a share, for the 2009 quarter.
A
poll of analysts by FactSet pegged Lilly at earning $1.15 a share, on revenue
of $5.79 billion.
Over
the past 52-week, the stock traded within the range of $32.02-$38.08. The stock
went down more than 2% year-to-date.
Alexion Pharmaceuticals, Inc.
(NASDAQ:ALXN) declined 3.19% to $66.23. The company said
that in Phase II trials, Soliris, a treatment for hemolytic uremic syndrome,
met its primary and key secondary endpoints.
The
company posted a higher-than-expected rise in quarterly profit, and signalled
that its genetic disorder drug was moving closer to approval in a new
indication.
Third-quarter
net income was $27.9 million, or 30 cents a share, compared to $26.7 million,
or 29 cents a share in the year-ago period.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today. For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
